Home Forums General Discussion “in use” study on drug product capsules packaged in blisters

Viewing 1 post (of 1 total)
  • Author
    Posts
  • John O’Neill
    Moderator
    Post count: 85

    Good question!

    In-use usually focuses on the product remaining in a bottle, having been exposed to more oxygen and moisture due to opening (and product jostling). I haven’t heard of a blister pack in-use study as yet, but it’s not unfathomable that a regulatory inspector could raise the issue.

    One response would be to explain that you do not conduct in-use for that package type with a strong justification that remaining product does not experience “exposure”.

    A second response would be to design an in-use study that assumes removing the blister pack from secondary packaging represents a challenge to the product (heat/humidity/light exposure potentials?) Additionally, if there is any possibility that pulling back the lidding on one pack could inadvertently damage the seal on a connected blister, that could be a basis for observation and evaluation. Some readers may be able to share further scenarios to test.

Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.